Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dakin

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinasesLes A Dakin, Michael H Block, Huawei Chen, et al.
Nature Neuroscience|March 18, 2008
Synaptic NMDA receptor activity boosts intrinsic antioxidant defensesSofia Papadia, Francesc X Soriano, Frédéric Léveillé, et al.
The New England Journal of Medicine|March 15, 2023
Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> VariantsOgo Egbuna, Brandon Zimmerman, George Manos, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2018
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinasesLakshmaiah Gingipalli, Michael H Block, Larry Bao, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activityPaul D Lyne, Brian Aquila, Donald J Cook, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2015
Discovery, design, and synthesis of indole-based EZH2 inhibitorsVictor S Gehling, Rishi G Vaswani, Christopher G Nasveschuk, et al.
Blood|December 24, 2013
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemiaErika K Keeton, Kristen McEachern, Keith S Dillman, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinasesLes A Dakin, Michael H Block, Huawei Chen, et al.
Nature Neuroscience|March 18, 2008
Synaptic NMDA receptor activity boosts intrinsic antioxidant defensesSofia Papadia, Francesc X Soriano, Frédéric Léveillé, et al.
The New England Journal of Medicine|March 15, 2023
Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> VariantsOgo Egbuna, Brandon Zimmerman, George Manos, et al.
Bioorganic & Medicinal Chemistry Letters|March 22, 2018
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinasesLakshmaiah Gingipalli, Michael H Block, Larry Bao, et al.
Bioorganic & Medicinal Chemistry Letters|December 23, 2008
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activityPaul D Lyne, Brian Aquila, Donald J Cook, et al.
Bioorganic & Medicinal Chemistry Letters|July 20, 2015
Discovery, design, and synthesis of indole-based EZH2 inhibitorsVictor S Gehling, Rishi G Vaswani, Christopher G Nasveschuk, et al.
Blood|December 24, 2013
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemiaErika K Keeton, Kristen McEachern, Keith S Dillman, et al.
Journal of Medicinal Chemistry|October 15, 2016
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell LymphomasRishi G Vaswani, Victor S Gehling, Les A Dakin, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Pageof 8